Agilent Completes AATI Acquisition, Strengthens Portfolio
Zacks Investment Research | Jun 04, 2018 07:56AM ET
Agilent Technologies, Inc. (NYSE:A) recently announced that it has successfully closed the acquisition of privately-held Advanced Analytical Technologies (“AATI”) for $250 million.
Post acquisition, AATI’s employees will join Agilent’s new Biomolecular Analysis Division within its Diagnostics and Genomics Group. In addition, the new division will consist of Agilent’s existing microfluidics business that was previously part of Agilent’s Life Sciences and Applied Markets Group.
The company recently announced fiscal second-quarter results on May 14. Following the announcement, the company’s share price fell 10%.
Shares of Agilent have slightly underperformed its industry on a year-to-date basis. The stock has registered a loss of 6.26% against the industry ’s growth of 2.26%.
Deal Details
As revealed, Ankeny, IA-based AATI is a developer of automated nucleic acid analysis systems using capillary electrophoresis methods. The company provides workflow solutions that include instruments, software and consumables. The solutions are extensively used for medical and molecular diagnostics for both commercial and research purposes.
The deal will strengthen Agilent’s capillary electrophoresis solutions portfolio. It will also expand the company’s footprint in varied industries like pharmaceutical, life sciences, agriculture and biofuels.
Acquisitions — Key Catalyst
Over the past few years, strategic acquisitions have played an important role in shaping Agilent’s growth trajectory.
Continuous strategic acquisitions should support Agilent to expand its product offerings, strengthen its footprint in the international markets and build customer base.
However, these acquisitions will likely keep Agilent’s operating margins under pressure, as it requires a significant amount of new investments.
Agilent Technologies, Inc. Price and Consensus
Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.